Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes (MDSs), yet identifying those patients unlikely to benefit remains challenging. We assessed response and overall survival (OS) in 247 patients molecularly profiled by next-generation sequencing (NGS) before f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Hunter, Anthony M., Komrokji, Rami S., Yun, Seongseok, Al Ali, Najla, Chan, Onyee, Song, Jinming, Hussaini, Mohammad, Talati, Chetasi, Sweet, Kendra L., Lancet, Jeffrey E., Padron, Eric, List, Alan F., Sallman, David A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2021
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903224/
https://ncbi.nlm.nih.gov/pubmed/33591325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003508
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares